Acute myeloid leukemia drug development in the post‐venetoclax era
Author:
Affiliation:
1. Division of HematologyUniversity of Colorado Department of Medicine Aurora Colorado
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25556
Reference48 articles.
1. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape
2. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia
3. New drugs creating new challenges in acute myeloid leukemia
4. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
5. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia;Haematologica;2023-04-13
2. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia;Blood Advances;2021-12-20
3. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues;Blood;2021-06-03
4. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia;Blood Reviews;2020-03
5. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia;Leukemia;2019-10-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3